[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100534848":3},{"organization":4,"armGroups":7,"interventions":19,"overallOfficials":25,"centralContacts":29,"locations":35,"responsibleParty":51,"collaborators":18,"id":53,"slug":54,"hasResults":55,"nctId":56,"briefTitle":57,"officialTitle":58,"acronym":18,"eligibilityCriteria":59,"healthyVolunteers":55,"sex":60,"minAge":61,"maxAge":18,"enrollmentInfo":62,"targetDuration":18,"studyType":65,"phases":66,"briefSummary":68,"conditions":69,"keywords":18,"overallStatus":37,"whyStopped":18,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Cardiff and Vale University Health Board","OTHER_GOV",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Intervention","EXPERIMENTAL","High flow oxygen therapy delivered via nasal cannalue",[13],"Other: High flow oxygen therapy",{"label":15,"type":16,"description":17,"interventionNames":18},"Control","NO_INTERVENTION","Standard care with oxygen therapy as required.",null,[20],{"type":21,"name":22,"description":23,"armGroupLabels":24,"otherNames":18},"OTHER","High flow oxygen therapy","High flow oxygen therapy delivered via nasal cannulae, at 50 litres flow with variable oxygen levels",[9],[26],{"name":27,"affiliation":5,"role":28},"Paul Twose","PRINCIPAL_INVESTIGATOR",[30],{"name":31,"role":32,"phone":33,"phoneExt":18,"email":34},"Paul Twose, MSc","CONTACT","07739315830","paul.twose@wales.nhs.uk",[36],{"facility":5,"status":37,"city":38,"state":18,"zip":39,"country":40,"countryCode":41,"cosmosGeoPoint":42,"geoPoint":47,"contacts":48},"RECRUITING","Cardiff","CF144XW","United Kingdom","UK",{"type":43,"coordinates":44},"Point",[45,46],-3.18,51.48,{"lat":46,"lon":45},[49],{"name":31,"role":32,"phone":18,"phoneExt":18,"email":50},"TwosePW@cardiff.ac.uk",{"type":52,"investigatorFullName":18,"investigatorTitle":18,"investigatorAffiliation":18,"oldNameTitle":18,"oldOrganization":18},"SPONSOR","100534848","high-flow-oxygen-therapy-after-spinal-cord-injury-100534848",false,"NCT06244160","High Flow Oxygen Therapy After Spinal Cord Injury","High Flow Oxygen Therapy After Spinal Cord Injury - Feasibility Study to Design a Pragmatic Randomised Controlled Trial Protocol","Inclusion Criteria:\n\n1. Spinal cord injury between C4 and T4 (Include ASIA A-D)\n2. Admitted to spinal injury ward within 24-48hours of injury\n\nExclusion Criteria:\n\n1. Aged under 18 years\n2. 3 or more rib fractures or flail\n3. Sternal fracture\n4. Concomitant lung injury\n5. Unable to gain informed consent from participant\n6. Contra-indication to using high flow therapy e.g., undrained pneumothorax, facial fractures, nasal obstruction, CSF leak, suspected or confirmed base of skull fracture, active epistaxis or recent functional endoscopic sinus surgery.","ALL","18 Years",{"count":63,"type":64},30,"ESTIMATED","INTERVENTIONAL",[67],"NA","The goal of this feasibility study is to learn about the ability to use a different form of oxygen therapy (known as high flow oxygen therapy) in patients who have a spinal cord injury in the upper back or neck.\n\nThe main questions it aims to answer are:\n\n1. Is it possible to recruit patients to the study\n2. It is possible to follow the protocol in its current format\n3. What is the impact on those receiving the intervention.\n\nParticipants will be randomised to receive either standard care or high flow oxygen therapy for 10 days following inclusion.",[70,71],"Spinal Cord Injuries","Respiratory Failure","2025-07-31",{"date":74,"type":75},"2025-08-05","ACTUAL",{"date":77,"type":75},"2024-04-01",{"date":79,"type":64},"2026-08",{"name":5,"class":6},1]